Antibody engineers seek optimal drug targeting TIGIT checkpoint

被引：0
|
作者：
Elie Dolgin
机构：
来源：
Nature Biotechnology | 2020年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.
引用
收藏
页码：1007 / 1009
页数：2
相关论文
共 50 条
  • [41] Cancer-targeting antibody–drug conjugates drive dealmaking frenzy
    Melanie Senior
    Nature Biotechnology, 2024, 42 : 362 - 366
  • [42] Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat
    Kamizuru, H
    Kimura, H
    Yasukawa, T
    Tabata, Y
    Honda, Y
    Ogura, Y
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2001, 42 (11) : 2664 - 2672
  • [43] FUNCTIONAL-DRUG TARGETING TO ERYTHROCYTES INVIVO USING ANTIBODY BEARING LIPOSOMES AS DRUG VEHICLES
    AGRAWAL, AK
    SINGHAL, A
    GUPTA, CM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 148 (01) : 357 - 361
  • [44] PRECLINICAL STUDIES SUPPORT CLINICAL DEVELOPMENT OF AZD2936, A MONOVALENT BISPECIFIC HUMANIZED ANTIBODY TARGETING PD-1 AND TIGIT
    Lee, Karin
    Malhotra, Deepali
    Pryts, Stacy
    Clancy-Thompson, Eleanor
    Omar, Bilal
    Naiman, Brian
    Overstreet, Michael
    Taylor, Devon
    Yang, Chunning
    Mulgrew, Kathy
    Xiao, Zhan
    Wang, Yue
    Moody, Gordon
    Cobbold, Mark
    Mazor, Yariv
    Hammond, Scott
    Pollizzi, Kristen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A489 - A489
  • [45] Antibody-Drug Conjugates to Treat Bacterial Biofilms via Targeting and Extracellular Drug Release
    Tvilum, Anne
    Johansen, Mikkel, I
    Glud, Laerke N.
    Ivarsen, Diana M.
    Khamas, Amanda B.
    Carmali, Sheiliza
    Mhatre, Snehit Satish
    Sogaard, Ane B.
    Faddy, Emma
    de Vor, Lisanne
    Rooijakkers, Suzan H. M.
    Ostergaard, Lars
    Jorgensen, Nis P.
    Meyer, Rikke L.
    Zelikin, Alexander N.
    ADVANCED SCIENCE, 2023, 10 (23)
  • [46] Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors
    Xue, Liqiong
    Wu, Lihua
    Tang, Wenbo
    Wang, Zhuoyi
    Xue, Junli
    Li, Qun
    Ge, Xiaoxiao
    Lin, Fengjuan
    Zhao, Wei
    Zhou, Jiuli
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting
    Francis, David M.
    Manspeaker, Margaret P.
    Archer, Paul A.
    Sestito, Lauren F.
    Heiler, Alexander J.
    Schudel, Alex
    Thomas, Susan N.
    BIOMATERIALS, 2021, 279
  • [48] Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates
    Zwaagstra, John C.
    Sulea, Traian
    Baardsnes, Jason
    Radinovic, Stevo
    Cepero-Donates, Yuneivy
    Robert, Alma
    O'Connor-McCourt, Maureen D.
    Tikhomirov, Ilia A.
    Jaramillo, Maria Luz
    PLOS ONE, 2019, 14 (12):
  • [49] Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
    Koefoed, Klaus
    Steinaa, Lucilla
    Soderberg, Josefine Nielsen
    Kjaer, Ida
    Jacobsen, Helle Jane
    Meijer, Per-Johan
    Haurum, John Sorensen
    Jensen, Allan
    Kragh, Michael
    Andersen, Peter Sejer
    Pedersen, Mikkel Wandahl
    MABS, 2011, 3 (06) : 584 - 595
  • [50] Optimal Physicochemical Properties of Antibody-Nanoparticle Conjugates for Improved Tumor Targeting
    Mittelheisser, Vincent
    Coliat, Pierre
    Moeglin, Eric
    Goepp, Lilian
    Goetz, Jacky G.
    Charbonniere, Loic J.
    Pivot, Xavier
    Detappe, Alexandre
    ADVANCED MATERIALS, 2022, 34 (24)
12345